HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmac

Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weigh

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and rai

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst

This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational c

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d

HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casda

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy a

This is the first study to comprehensively interconnect clinical outcomes from patients receiving a

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d

Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rati

Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight

Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.02) per share which missed the analys

Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declin

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and rai

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises

Leerink Partners analyst Geoffrey Porges maintains Arcus Biosciences (NYSE:RCUS) with a Outperfor

HC Wainwright & Co. analyst Emily Bodnar reiterates Arcus Biosciences (NYSE:RCUS) with a Buy

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.89) per share which beat the analyst

Wells Fargo analyst Eva Fortea Verdejo downgrades Arcus Biosciences (NYSE:RCUS) from Overweight t

Goldman Sachs analyst Richard Law upgrades Arcus Biosciences (NYSE:RCUS) from Neutral to Buy and

Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan,

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy a

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal can

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly ear

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

  On Thursday, 369 companies hit new 52-week lows.

Gainers AgileThought, Inc. (NASDAQ: AGIL) jumped 85.5% to $0.3941. AgileThought recently posted a

U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording gains

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss a

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn